# Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
Canonical URL: https://biopharmsignal.com/news/PSTV/plus-therapeutics-receives-medicare-enrollment-approval-for-cnside-diagnostic
Ticker: PSTV
Company: PLUS THERAPEUTICS, Inc.
Source: PLUS THERAPEUTICS, Inc.
Published: 2026-05-07 11:30 EST
Original Source URL: https://ir.plustherapeutics.com
## Summary

Enables billing under traditional Medicare and creates a pathway to ~35 million Medicare Advantage beneficiaries through future payer coverage decisions HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and

## Article Body
Enables billing under traditional Medicare and creates a pathway to ~35 million Medicare Advantage beneficiaries through future payer coverage decisions HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and
## Recent Company News
- 2026-06-04 11:30 EST — [Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory](https://biopharmsignal.com/news/PSTV/plus-therapeutics-announces-cap-accreditation-of-cnsider-diagnostics-clinical-laboratory) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-26 11:30 EST — [Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases](https://biopharmsignal.com/news/PSTV/plus-cnside-diagnostic-platform-demonstrates-substantial-healthcare-cost-reduction-in-patients-with-leptomeningeal-metastases) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-19 11:30 EST — [Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology](https://biopharmsignal.com/news/PSTV/plus-therapeutics-partners-with-ephemeral-technologies-to-deploy-ai-execution-platform-for-cns-oncology) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-15 20:05 EST — [Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout](https://biopharmsignal.com/news/PSTV/plus-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update-on-reyobiqtm-clinical-program-and-cnsider-commercial-rollout) — Source: PLUS THERAPEUTICS, Inc.
- 2026-05-08 11:30 EST — [Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases](https://biopharmsignal.com/news/PSTV/plus-therapeutics-announces-oral-presentation-highlighting-reyobiqtm-clinical-and-translational-data-demonstrating-favorable-safety-survival-and-emerging-immunomodulation-in-leptomeningeal-metastases) — Source: PLUS THERAPEUTICS, Inc.
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)